Invasive lobular carcinoma of the breast is the most common 'special'morphological subtype
of breast cancer, comprising up to 15% of all cases. Tumours are generally of a good …

Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and
aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by …

Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for
patients with invasive ductal or lobular carcinoma. Patients and Methods Patients diagnosed …

Oestrogen-related receptors (ERRs) are orphan nuclear receptors that were initially
investigated in breast cancer because of their structural relationship to oestrogen receptors …

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast
cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological …

Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancers in the United
States, 80% of which are estrogen receptor (ER)-positive, with an unusual metastatic pattern …

Resistance to chemotherapy is a major complication in the treatment of advanced breast
cancer. Estrogens and prolactin (PRL) are implicated in the pathogenesis of breast cancer …

Progesterone and estrogen are important drivers of breast cancer proliferation. Herein, we
probed estrogen receptor-α (ER) and progesterone receptor (PR) cross-talk in breast cancer …

Invasive lobular carcinoma (ILC) is a histologic subtype of breast cancer that is frequently
associated with favorable outcomes, as approximately 90% of ILC express the estrogen …

Estrogen receptor alpha (ER/ESR1) is frequently mutated in endocrine resistant ER-positive
(ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the …